Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Prothena Corporation plc PRTA

Healthcare Biotechnology
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the... see more

Recent & Breaking News (NDAQ:PRTA)

Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update

GlobeNewswire February 11, 2021

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 5, 2021

Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th

GlobeNewswire February 4, 2021

Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA

GlobeNewswire February 1, 2021

Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis

GlobeNewswire December 9, 2020

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 4, 2020

Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update

GlobeNewswire November 4, 2020

Prothena Announces Presentations on Two Programs from its Alzheimer's Disease Portfolio at CTAD 2020

GlobeNewswire November 4, 2020

Prothena to Report Third Quarter 2020 Financial Results on November 4

GlobeNewswire October 28, 2020

Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson's Disease

GlobeNewswire October 20, 2020

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 2, 2020

Prothena to Hold Investor Webcast to Discuss Results from Phase 2 PASADENA Study Presented at the International Parkinson and Movement Disorder Society's MDS Virtual Congress

GlobeNewswire September 15, 2020

Prasinezumab Slows Progression on Measures of Parkinson's Disease in Phase 2 Study

GlobeNewswire September 11, 2020

Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15

GlobeNewswire September 8, 2020

Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson's Disease and Movement Disorders

GlobeNewswire September 3, 2020

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 2, 2020

Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update

GlobeNewswire August 6, 2020

Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson's Disease and Movement Disorders

GlobeNewswire August 5, 2020

Prothena to Report Second Quarter 2020 Financial Results on August 6

Thomson Reuters ONE July 30, 2020

Prothena to Present at the Jefferies Virtual Healthcare Conference on June 3

GlobeNewswire May 27, 2020